Marshall Wace, LLP Nuvectis Pharma, Inc. Transaction History
Marshall Wace, LLP
- $72.2 Billion
- Q2 2024
A detailed history of Marshall Wace, LLP transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 33,868 shares of NVCT stock, worth $209,304. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,868
Previous 50,068
32.36%
Holding current value
$209,304
Previous $410,000
47.8%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding NVCT
# of Institutions
41Shares Held
1.77MCall Options Held
0Put Options Held
0-
Ronit Capital LLP563KShares$3.48 Million5.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA251KShares$1.55 Million0.0% of portfolio
-
Baldwin Brothers LLC169KShares$1.04 Million0.08% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny119KShares$738,2560.0% of portfolio
-
Black Rock Inc. New York, NY83.4KShares$515,4860.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $90.5M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...